BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 19443659)

  • 1. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.
    Alousi AM; Weisdorf DJ; Logan BR; Bolaños-Meade J; Carter S; Difronzo N; Pasquini M; Goldstein SC; Ho VT; Hayes-Lattin B; Wingard JR; Horowitz MM; Levine JE;
    Blood; 2009 Jul; 114(3):511-7. PubMed ID: 19443659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.
    Bolaños-Meade J; Wu J; Logan BR; Levine JE; Ho VT; Alousi AM; Weisdorf DJ; Luznik L;
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):481-5. PubMed ID: 23247045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel strategies for steroid-refractory acute graft-versus-host disease.
    Bolaños-Meade J; Vogelsang GB
    Curr Opin Hematol; 2005 Jan; 12(1):40-4. PubMed ID: 15604890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-versus-host disease treatment: predictors of survival.
    Levine JE; Logan B; Wu J; Alousi AM; Ho V; Bolaños-Meade J; Weisdorf D;
    Biol Blood Marrow Transplant; 2010 Dec; 16(12):1693-9. PubMed ID: 20541024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.
    Levine JE; Paczesny S; Mineishi S; Braun T; Choi SW; Hutchinson RJ; Jones D; Khaled Y; Kitko CL; Bickley D; Krijanovski O; Reddy P; Yanik G; Ferrara JL
    Blood; 2008 Feb; 111(4):2470-5. PubMed ID: 18042798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.
    Jacobson PA; Huang J; Wu J; Kim M; Logan B; Alousi A; Grimley M; Bolaños-Meade J; Ho V; Levine JE; Weisdorf D
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):421-9. PubMed ID: 19925875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.
    Bolaños-Meade J; Logan BR; Alousi AM; Antin JH; Barowski K; Carter SL; Goldstein SC; Hexner EO; Horowitz MM; Lee SJ; Levine JE; MacMillan ML; Martin PJ; Mendizabal AM; Nakamura R; Pasquini MC; Weisdorf DJ; Westervelt P; Ho VT
    Blood; 2014 Nov; 124(22):3221-7; quiz 3335. PubMed ID: 25170121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Gatza E; Braun T; Levine JE; Ferrara JL; Zhao S; Wang T; Chang L; Harris A; Pawarode A; Kitko C; Magenau JM; Yanik GA; Couriel DR; Goldstein S; Connelly J; Reddy P; Paczesny S; Choi SW
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1426-34. PubMed ID: 24892263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease.
    Kennedy GA; Butler J; Western R; Morton J; Durrant S; Hill GR
    Bone Marrow Transplant; 2006 Jun; 37(12):1143-7. PubMed ID: 16699531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis.
    Perkins J; Field T; Kim J; Kharfan-Dabaja MA; Fernandez H; Ayala E; Perez L; Xu M; Alsina M; Ochoa L; Sullivan D; Janssen W; Anasetti C
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):937-47. PubMed ID: 20102746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol.
    Yanik GA; Horowitz MM; Weisdorf DJ; Logan BR; Ho VT; Soiffer RJ; Carter SL; Wu J; Wingard JR; Difronzo NL; Ferrara JL; Giralt S; Madtes DK; Drexler R; White ES; Cooke KR
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):858-64. PubMed ID: 24607553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.
    Baron F; Sandmaier BM; Storer BE; Maris MB; Langston AA; Lange T; Petersdorf E; Bethge W; Maziarz RT; McSweeney PA; Pulsipher MA; Wade JC; Chauncey TR; Shizuru JA; Sorror ML; Woolfrey AE; Maloney DG; Storb R
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1041-8. PubMed ID: 17697966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
    Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
    Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.
    Kitko CL; Braun T; Couriel DR; Choi SW; Connelly J; Hoffmann S; Goldstein S; Magenau J; Pawarode A; Reddy P; Schuler C; Yanik GA; Ferrara JL; Levine JE
    Biol Blood Marrow Transplant; 2016 May; 22(5):862-8. PubMed ID: 26551636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.